Global license and collaboration agreement set to advance the development of OSE-230, a monoclonal antibody aimed at resolving chronic inflammation. ...
Bristol Myers Squibb (NYSE: BMY) announced that it has successfully completed its acquisition of RayzeBio, Inc. (NASDAQ: RYZB). With the completion of the ...
Fujifilm Irvin Technology is a leader in the innovation and manufacturing of cell culture solutions in the global life sciences and medical markets. With t...
Bitterroot Bio, a leader in innovative treatments for cardiovascular diseases, and Biotheus, a pioneer in monoclonal and multi-specific antibody design, an...
Biological E. Limited (BE) to Manufacture Up to 50 Million Doses of QDENGA Per Year, Accelerating Takeda’s Ability to Deliver 100 Million Doses Per...
SIMLANDI is the first citrate-free, high-concentration biosimilar to be designated interchangeable to Humira in the U.S. SIMLANDI is the first biosimil...
Sanofi-Aventis Groupe announced promising results from its Phase 2 RILECSU study, showcasing rilzabrutinib's ability to significantly reduce itch severity ...
LimmaTech Biologics AG, announced encouraging interim results from its Phase I/II clinical trial evaluating Shigella4V (S4V), a promising tetravalent bioco...
LabVantage Solutions, Inc., the premier provider of laboratory informatics solutions and services, has launched an integrated, digitally native ecosystem t...
Aleta Biotherapeutics (Aleta), a pioneer in immuno-oncology with a focus on CAR T-Cell Engager (CTE) platforms, in collaboration with Cancer Research UK&rs...
In a bold move, Vaccinex has forged eight new antibody discovery agreements with leading pharmaceutical and biotechnology companies, as well as str...
"This new partnership builds on our innovation strategy and will allow us to explore the innovative approach of IL-21 blockage as a possible new pa...
ProNephro AKI (NGAL) stands out as the first AKI biomarker test to secure FDA clearance for pediatric use, covering children from...
ChatGPT CAMBRIDGE, Mass.--(BUSINESS WIRE)--February 16, 2024 07:00 AM Eastern Standard Time Sarepta Therapeutics, Inc. (NASDAQ:...
© 2024 Biopharma Boardroom. All Rights Reserved.
